Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.49 USD | +7.82% | +11.16% | -31.02% |
03-25 | Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-12 | Top Premarket Decliners | MT |
Business Summary
Number of employees: 1
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biological Drugs
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -87.57% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -87.57% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Matthew Blischak
CEO | Chief Executive Officer | - | 15/05/23 |
Lance Thibault
DFI | Director of Finance/CFO | 58 | 15/05/23 |
Sonia Timberlake
CTO | Chief Tech/Sci/R&D Officer | - | - |
Matthew Nelson
PRN | Corporate Officer/Principal | - | 30/06/21 |
Michelle L. Rose
LAW | General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Susan Graf
CHM | Chairman | 52 | 22/04/21 |
Jeffery Smisek
BRD | Director/Board Member | 69 | 31/08/17 |
Chris W. Shumway
BRD | Director/Board Member | 58 | 31/08/20 |
Director/Board Member | 58 | 24/09/19 | |
Christian Lange
BRD | Director/Board Member | 44 | 31/08/17 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,605,763 | 746,985 ( 46.52 %) | 0 | 46.52 % |
Company contact information
Finch Therapeutics Group, Inc.
75 State Street Suite 100
02109, Boston
+
http://www.finchtherapeutics.comSector
1st Jan change | Capi. | |
---|---|---|
-31.02% | 3.71M | |
+26.28% | 42.68B | |
-3.99% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.36% | 24.94B | |
-21.47% | 18.96B | |
+27.58% | 12.3B | |
-2.75% | 11.95B | |
-2.02% | 11.55B |
- Stock Market
- Equities
- FNCH Stock
- Company Finch Therapeutics Group, Inc.